Photon Counting Computed Tomography in Heart Failure Patients
NCT ID: NCT06964672
Last Updated: 2025-05-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
150 participants
OBSERVATIONAL
2025-06-01
2030-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Recent technological advances in the field of CT imaging have nevertheless paved the way to explore new pathways of myocardial viability assessment even in patients traditionally deemed unsuitable for CMR. The introduction of photon-counting detectors, in particular, is expected to be the next major breakthrough in clinical x-ray computed tomography (CT). Photon-counting detector (PCD)-CT will overcome several shortcomings and limitations of current CT systems: it might substantially improve and expand the applicability of CT imaging by offering intrinsic spectral capabilities, increased spatial resolution, reduced electronic noise and improved image contrast. On the basis of this physical principle PCCT has the promise to improve the actual not fully satisfactory quality of scar visualization in CT images. In particular, conventional scanners are affected by a limited contrast resolution which lead to a variable and relevant rate of false negative myocardial scar-free images depending on the assessor expertise. The constant improving of CT diagnostic field have been revolutionizing the diagnostic workflow in several cardiac disease. Late contrast enhancement CT demonstrated an adequate accuracy to detect and discriminate the etiology of both ischemic and non-ischemic causes of myocardial injury compared to actual gold standard exams in patients with a troponin-positive acute chest pain syndrome. The same technique showed good sensitivity, specificity and a high negative predictive value (95%) for the identification of myocardial scars imputed to be an anatomical substrate of ventricular tachycardia with a proper concordance with electro-anatomic mapping findings (k=0.536). Finally, this enormous potential of CT implementation with the novel PCCT will provide not only the possibility to further study myocardial viability, but also is expected to be superior to standard CT exams in details definition, reduction of electronic noise and increase of spatial resolution, with consequent specific advantages in patients with heart failure, especially those with artificial devices with metallic components, in which adverse event identification and definition (such as inflow or outflow thrombosis) is complex. Thanks to these multiple diagnostic and therapeutic advantages, in combination with the availability of the PCCT device, the use of such technique is now the preferred cardiac imaging examination for the study of cardiac anatomy and function in patients with severe heart failure and a contraindication to perform the gold standard CMR. Thus, we planned a single-center observational study to asses the performance of PCCT in the identification of myocardial scars and patterns in critically ill patients with severe heart failure.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Use of Point-of-Care Ultrasound (POCUS) to Reduce Hospital Length of Stay in Patients With Heart Failure ( POCUSHF )
NCT06965712
Peripheral Venous Oxygen Saturation and Biomarkers to Estimate Cardiac Output and Filling Pressures in Heart Failure
NCT00595738
Speckle Tracking Echocardiography Adds Information in Decompensated Heart Failure
NCT03009552
Characterization of Heart Failure With Preserved Ejection Fraction
NCT03197350
Treating Heart Failure With Enhanced External Counterpulsation (EECP)
NCT03021213
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical need for a CT exam with angiographic evaluation and scar imaging
* Contraindication to perform a Magnetic Resonance Imaging.
* All ages
* Signature of Informed Consent
Exclusion Criteria
* Absence of clinical indication to a CT exam
* Contraindication to perform a CT exam.
* Pregnancy
* Refusal to provide Informed Consent to participate to the study
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dr Anna Mara Scandroglio
UNKNOWN
Prof Antonio Esposito
UNKNOWN
Prof Anna Palmisano
UNKNOWN
Università Vita-Salute San Raffaele
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Marina Pieri
MD
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Antonio Esposito, Professor
Role: CONTACT
References
Explore related publications, articles, or registry entries linked to this study.
Pieri M, Ortalda A, Altizio S, Bertoglio L, Nardelli P, Fominskiy E, Lapenna E, Ajello S, Scandroglio AM. Prolonged Impella 5.0/5.5 support within different pathways of care for cardiogenic shock: the experience of a referral center. Front Cardiovasc Med. 2024 Jul 2;11:1379199. doi: 10.3389/fcvm.2024.1379199. eCollection 2024.
Barac YD, Nevo A, Schroder JN, Milano CA, Daneshmand MA. LVAD Outflow Graft Role in Pump Thrombosis. ASAIO J. 2020 Feb;66(2):128-131. doi: 10.1097/MAT.0000000000000936.
Ajello S, Pieri M, Bertoglio L, Altizio S, Nardelli P, Scandroglio AM. Extrinsic outflow graft flow obstruction in patients with HeartMate3 LVAD. Artif Organs. 2023 Apr;47(4):786-790. doi: 10.1111/aor.14450. Epub 2022 Nov 17.
Esposito A, Palmisano A, Antunes S, Maccabelli G, Colantoni C, Rancoita PMV, Baratto F, Di Serio C, Rizzo G, De Cobelli F, Della Bella P, Del Maschio A. Cardiac CT With Delayed Enhancement in the Characterization of Ventricular Tachycardia Structural Substrate: Relationship Between CT-Segmented Scar and Electro-Anatomic Mapping. JACC Cardiovasc Imaging. 2016 Jul;9(7):822-832. doi: 10.1016/j.jcmg.2015.10.024. Epub 2016 Feb 17.
Palmisano A, Vignale D, Tadic M, Moroni F, De Stefano D, Gatti M, Boccia E, Faletti R, Oppizzi M, Peretto G, Slavich M, Sala S, Montorfano M, Agricola E, Margonato A, De Cobelli F, Gentile F, Robella M, Cortese G, Esposito A. Myocardial Late Contrast Enhancement CT in Troponin-Positive Acute Chest Pain Syndrome. Radiology. 2022 Mar;302(3):545-553. doi: 10.1148/radiol.211288. Epub 2021 Dec 7.
Palmisano A, Vignale D, Benedetti G, Del Maschio A, De Cobelli F, Esposito A. Late iodine enhancement cardiac computed tomography for detection of myocardial scars: impact of experience in the clinical practice. Radiol Med. 2020 Feb;125(2):128-136. doi: 10.1007/s11547-019-01108-7. Epub 2019 Nov 29.
Sartoretti T, Wildberger JE, Flohr T, Alkadhi H. Photon-counting detector CT: early clinical experience review. Br J Radiol. 2023 Jul;96(1147):20220544. doi: 10.1259/bjr.20220544. Epub 2023 Feb 10.
Danielsson M, Persson M, Sjolin M. Photon-counting x-ray detectors for CT. Phys Med Biol. 2021 Jan 29;66(3):03TR01. doi: 10.1088/1361-6560/abc5a5.
Bock A, Estep JD. Myocardial viability: heart failure perspective. Curr Opin Cardiol. 2019 Sep;34(5):459-465. doi: 10.1097/HCO.0000000000000651.
Patel AR, Salerno M, Kwong RY, Singh A, Heydari B, Kramer CM. Stress Cardiac Magnetic Resonance Myocardial Perfusion Imaging: JACC Review Topic of the Week. J Am Coll Cardiol. 2021 Oct 19;78(16):1655-1668. doi: 10.1016/j.jacc.2021.08.022.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Bohm M, Burri H, Butler J, Celutkiene J, Chioncel O, Cleland JGF, Coats AJS, Crespo-Leiro MG, Farmakis D, Gilard M, Heymans S, Hoes AW, Jaarsma T, Jankowska EA, Lainscak M, Lam CSP, Lyon AR, McMurray JJV, Mebazaa A, Mindham R, Muneretto C, Francesco Piepoli M, Price S, Rosano GMC, Ruschitzka F, Kathrine Skibelund A; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368. No abstract available.
Al-Sabeq B, Nabi F, Shah DJ. Assessment of myocardial viability by cardiac MRI. Curr Opin Cardiol. 2019 Sep;34(5):502-509. doi: 10.1097/HCO.0000000000000656.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PCCT-HF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.